STOCK TITAN
  1. Home
  2. News
  3. MBOT

Microbot Medical, Inc. - MBOT STOCK NEWS

Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.

Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.

One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.

Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.

Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.

Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.

For further information about Microbot Medical, please visit www.microbotmedical.com.

News

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

Rhea-AI Summary
Microbot Medical Inc. (MBOT) has signed a Settlement Agreement and Release with several entities, resolving all claims asserted against the Company in a lawsuit filed in 2020. The settlement amount, over half of which will be covered by Microbot's insurance carrier, will not impact the company's cash position or balance sheet. CEO Harel Gadot believes that resolving this matter while maintaining the company's cash position is in the best interest of shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announces the addition of a US-based Clinical Research Associate (CRA) to support its anticipated IDE submission for its first in human clinical trial following positive results of its pivotal GLP pre-clinical study. The CRA will join the established clinical team in the USA, led by Dr. Juan Diaz-Cartelle, the Company’s Chief Medical Officer. This move aims to establish the right infrastructure for clinical trial execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
clinical trial
-
News

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announced the immediate exercise of certain outstanding preferred investment options to purchase up to 1,685,682 shares of common stock at a reduced exercise price of $1.62 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
News

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of its GLP pivotal pre-clinical study for its LIBERTY® Endovascular Robotic Surgical System. The study, conducted using a porcine model, involved 96 robotic navigations and resulted in positive outcomes in the histopathology report. The Company plans to submit its IDE application to the FDA and commence its pivotal human clinical trial soon, marking an important milestone in its transition to a clinically stage company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.3%
Tags
clinical trial
-
News

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) collaborates with Corewell Health™ to evaluate LIBERTY® Robotic Surgical System for remote endovascular treatments. The agreement aims to enable telerobotics between remote centers, led by Dr. Ryan Madder, M.D., an interventional cardiology expert.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
News

Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed its GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System. The study results will support the company's IDE submission to the FDA for commencing the human clinical study. Three leading interventional radiologists conducted the study, utilizing the robotic system for 96 navigations, leading to positive histopathology report outcomes. The CEO, Harel Gadot, expressed confidence in the company's transition to the clinical, regulatory, and pre-commercial phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
clinical trial
News

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

Rhea-AI Summary
Microbot Medical Inc. (MBOT) appoints Dr. Juan Diaz-Cartelle, former Senior Medical Director at Boston Scientific Corporation, as its new Chief Medical Officer. Dr. Diaz-Cartelle's appointment coincides with the Company's transition to focus on U.S.-based activities, including clinical trials and FDA regulatory processes for the LIBERTY Endovascular Robotic Surgical System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
management
-
News

Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This achievement is a crucial step towards the company's regulatory submission and the FDA's approval for clinical trials. The V&V process ensures that the product aligns with specified requirements and serves its intended purpose, highlighting Microbot's commitment to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
News

Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announced the granting of the 'One & Done®' trademark from the US Patent and Trademark Office for its LIBERTY Robotic Surgical System, highlighting its unique feature of integrating guidewires, microcatheters, and other instruments for endovascular procedures. This move expands the company's proprietary assets and sets its product apart in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
News

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study

Rhea-AI Summary
Microbot Medical Inc. announces 100% success rate in reaching targets with no adverse events in pre-clinical study using the LIBERTY Robotic Surgical System. The study involved 48 animal targets and visual examination after 72 hours showed no evidence of vascular injury or adverse events. 6 LIBERTY Systems were used, all performing flawlessly with 100% usability and technical success. The company plans to submit an IDE application to the FDA for a pivotal clinical trial in humans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
clinical trial

FAQ

What is the current stock price of Microbot Medical (MBOT)?

The current stock price of Microbot Medical (MBOT) is $0.9745 as of December 20, 2024.

What is the market cap of Microbot Medical (MBOT)?

The market cap of Microbot Medical (MBOT) is approximately 16.6M.

What is Microbot Medical, Inc.?

Microbot Medical, Inc. is a pre-clinical medical device company specializing in developing next-generation micro-robotic medical technologies for minimally invasive procedures.

What is the LIBERTY Endovascular Robotic Surgical System?

The LIBERTY Endovascular Robotic Surgical System is an innovative platform aimed at improving endovascular procedures by eliminating the need for large, cumbersome equipment while reducing radiation exposure and physician strain.

What recent achievements has Microbot Medical accomplished?

Microbot Medical recently achieved positive results from its pivotal GLP pre-clinical study and submitted an IDE application to the FDA, paving the way for its first human clinical trials.

What are the core technologies developed by Microbot Medical?

Microbot Medical's core technologies include the Virob platform, an autonomous advancing micro-robot, and the LIBERTY Endovascular Robotic Surgical System.

What is the vision of Microbot Medical?

Microbot Medical aims to transform minimally invasive surgeries by providing cutting-edge micro-invasive technologies that help physicians target disease sites with unmatched precision.

How is Microbot Medical preparing for commercialization?

Microbot Medical is engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for its technologies once regulatory approvals are obtained.

What impact do recent geopolitical events have on Microbot Medical's operations?

Despite recent geopolitical events in Israel, Microbot Medical's operations in Israel, the USA, and other parts of the globe remain uninterrupted, and the company believes it will achieve its regulatory and commercial milestones as scheduled.

What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?

The Self-Cleaning Shunt (SCS) is another innovative platform developed by Microbot Medical aimed at improving the quality of life for patients by providing less invasive and more precise solutions for surgical procedures.

Who is acting as the exclusive placement agent for Microbot Medical's offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for Microbot Medical's offering.

How can I get more information about Microbot Medical?

For more information about Microbot Medical, you can visit their website at www.microbotmedical.com.

Stock MBOT logo
Microbot Medical, Inc.

Nasdaq:MBOT

MBOT Rankings

#5385 Ranked by Market Cap
N/A Ranked by Dividends

MBOT Stock Data

16.59M
16.69M
1.43%
7.46%
3.43%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
HINGHAM